Inventor

Bernard Moss

Inventor

Bethesda, MD, US

Overview

1988–2021

Patent span

Chemistry

Primary field (CPC C)

Patents· 44 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C12Nprimary

C12NMicroorganisms or enzymes29%

A61KPreparations for medical, dental or toiletry purposes26%

C07KPeptides24%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations13%

Y02ATechnologies for adaptation to climate change4%

G01NInvestigating or analysing materials by determining their chemical or physical properties3%

C12YEnzymes1%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests1%

PatentTitleYear

10,894,966Virus-based expression vectors and uses thereof2021 10,421,978Intergenic sites between conserved genes in the genome of modified vaccinia ankara (MVA) vaccinia virus2019 9,879,231'Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites'2018 9,708,392'Monoclonal antibodies against orthopoxviruses'2017 9,453,239'Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes'2016 9,254,319'Compositions and methods for generating an immune response'2016 9,133,478'Modified vaccinia Ankara (MVA) virus recombinants comprising heterologous coding sequences inserted into the intergenic regions between essential genes'2015 9,133,480'Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites'2015 8,999,336'Monoclonal antibodies against Orthopoxviruses'2015 8,916,172'MVA expressing modified HIV envelope, gag, and pol genes'2014 8,506,947'Vaccinia virus expression vector for selective replication in a tumor cell and introduction of exogenous nucleotide sequence into a tumor cell'2013 8,404,818'Monoclonal antibodies against orthopoxviruses'2013 8,124,105'Compositions, methods and kits relating to poxvirus subunit vaccines'2012 7,914,788'Monoclonal antibodies against orthopoxviruses'2011 7,867,982'MVA expressing modified HIV envelope, gag, and pol genes'2011 7,560,116'Compositions, methods and kits relating to poxvirus subunit vaccines'2009 7,494,813'VAC-BAC shuttle vector system'2009 7,303,754'MVA expressing modified HIV envelope, gag, and pol genes'2007 7,208,313'Combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector'2007 7,045,313'Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA'2006 7,045,136'Methods of immunization using recombinant poxviruses having foreign DNA expressed under the control of poxvirus regulatory sequences'2006 7,015,024'Compositions containing recombinant poxviruses having foreign DNA expressed under the control of poxvirus regulatory sequences'2006 6,998,252'Recombinant poxviruses having foreign DNA expressed under the control of poxvirus regulatory sequences'2006 6,780,417'Transmission blocking immunogen from malaria'2004 6,171,596'Oligomeric HIV-1 envelope glycoproteins'2001 6,039,957'Oligomeric HIV-1 envelope glycoproteins'2000 5,866,383'In vitro ligation of foreign DNA into large eukaryotic viruses'1999 5,849,304'Recombinant vaccinia virus expressing human retrovirus gene'1998 5,770,210'Recombinant vaccinia virus expressing human retrovirus gene'1998 5,676,950'Enterically administered recombinant poxvirus vaccines'1997 5,587,455'Cytotoxic agent against specific virus infection'1996 5,550,035'Prokaryotic expression in eukaryotic cells'1996 5,506,138'Recombinant vaccinia virus encoding cytochromes P-450'1996 5,428,143'Cytotoxic agent against specific virus infection'1995 5,348,741'Vector for recombinant poxvirus expressing rabies virus glycoprotein'1994 5,336,758'Peptides stimulating cytotoxic T cells immune to HIV RT'1994 5,206,353'CD-4/cytotoxic gene fusions'1993 5,187,268'Gene encoding an anti-complement protein from vaccinia'1993 5,164,313'Recombinant vaccinia virus encoding cytochromes P-450'1992 5,157,110'Synthetic, anti-complement protein'1992 5,151,509'Gene encoding serine protease inhibitor'1992 5,135,855'Rapid, versatile and simple system for expressing genes in eukaryotic cells'1992 5,126,251'Stable mammalian cell line expressing a bacteriophage RNA polymerase'1992 4,738,846'Vaccine for vesicular stomatitis virus'1988

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1988–2021Based in Bethesda, MD, US· patent location history

1992–2021Patents assigned to US HEALTH (29)· patent assignee history

1993–1998Patents assigned to US COMMERCE (5)· patent assignee history

2011–2016Patents assigned to UNIV EMORY (4)· patent assignee history

2012–2016Patents assigned to MOSS BERNARD (7)· patent assignee history

2013–2015Patents assigned to EARL PATRICIA (3)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
US HEALTH	29	1992–2021
MOSS BERNARDself	7	2012–2016
US COMMERCE	5	1993–1998
UNIV EMORY	4	2011–2016
EARL PATRICIA	3	2013–2015

Locations

Location	Patents	Span
Bethesda, Maryland, US	44	1988–2021